AstraZeneca PLC Director/PDMR Shareholding (5565R)
June 30 2020 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 5565R
AstraZeneca PLC
30 June 2020
30 June 2020 15:00 BST
Transaction by Person Discharging Managerial
Responsibilities
Disclosure under Article 19 of the EU Market Abuse
Regulation
AstraZeneca PLC (the Company) announces that, on 29 June 2020,
it was notified by Pascal Soriot, Chief Executive Officer, that, on
29 June 2020, Mr Soriot ceased to be beneficially interested in
127,389 Ordinary Shares of $0.25 each in the Company, following the
gift of those shares to family members for nil consideration.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Pascal Soriot
---------------------------- -------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Chief Executive Officer
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name AstraZeneca PLC
---------------------------- -------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
---------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
---------------------------- -------------------------------------
b) Nature of the transaction Gift of shares to family members
for nil consideration
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 127,389
----------
---------------------------- -------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
---------------------------- -------------------------------------
e) Date of the transaction 29 June 2020
---------------------------- -------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------- -------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @ AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHURUARRKUNOAR
(END) Dow Jones Newswires
June 30, 2020 10:00 ET (14:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024
